Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)PRNewsWire • 01/24/22
U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic ArthritisPRNewsWire • 01/21/22
FDA Gives Back To Back Approval To Pfizer's & AbbVie's JAK Inhibitors For Atopic DermatitisBenzinga • 01/18/22
FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & OlderBenzinga • 01/18/22
U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic DermatitisPRNewsWire • 01/14/22
AbbVie Inc. (ABBV) Management Presents at JPMorgan 40th Annual Healthcare Conference (Transcript)Seeking Alpha • 01/12/22
AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025PRNewsWire • 01/11/22